Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28775928 | 0.84 | CYP3A4 (0.45) | CYP3A4IMPDH2PRMT3ROCK2ABL1 | |
| SCHEMBL4877927 | 0.81 | PPARA (0.53) | CYP3A4SLC22A12CYP1A2 | |
| SCHEMBL1536335 | 0.78 | PRKCZ (0.44) | CYP3A4IMPDH2ABL1CYP1A2CYP2D6 | |
| SCHEMBL8414749 | 0.76 | CYP3A4 (0.51) | CYP3A4IMPDH2PRMT3ROCK2 | |
| SCHEMBL10733316 | 0.76 | PPARA (0.53) | CYP3A4SLC22A12CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL28033590 | 0.75 | PRKCZ (0.42) | CYP3A4IMPDH2ROCK2CYP1A2CYP2D6 | |
| SCHEMBL4514734 | 0.74 | LATS1 (0.40) | SLC22A12 | |
| SCHEMBL4028110 | 0.74 | CYP11B2 (0.51) | CYP3A4ABL1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25005753 | 0.74 | ROCK2 (0.53) | CYP3A4ROCK2 | |
| SCHEMBL13291029 | 0.73 | IKBKB (0.48) | CYP3A4ABL1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | IRM LLC (BM) | 2009-01-08 | — | — | US | disclosed |
| EP-1979347-A2 | POLYCYCLIC 1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089557-A2 | POLYCYCLIC 1, 2, 3, 4 -TETRAHYDRO- ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012097-A1 | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators | PPARG, PPARD, PPARA | CYP3A4 787/4885IMPDH2 1972/4885PRMT3 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.